NZ591146A - Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills - Google Patents

Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills

Info

Publication number
NZ591146A
NZ591146A NZ591146A NZ59114609A NZ591146A NZ 591146 A NZ591146 A NZ 591146A NZ 591146 A NZ591146 A NZ 591146A NZ 59114609 A NZ59114609 A NZ 59114609A NZ 591146 A NZ591146 A NZ 591146A
Authority
NZ
New Zealand
Prior art keywords
aggregates
stem cell
mesenchymal stem
micomills
composition
Prior art date
Application number
NZ591146A
Other languages
English (en)
Inventor
Alla Danilkovich
Robert E Newman
Samson Tom
Christopher Ton
Zhanling Wang
Randal Young
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591146(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Priority to NZ602248A priority Critical patent/NZ602248A/en
Publication of NZ591146A publication Critical patent/NZ591146A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NZ591146A 2008-08-14 2009-08-14 Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills NZ591146A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ602248A NZ602248A (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8889808P 2008-08-14 2008-08-14
PCT/US2009/053891 WO2010019886A1 (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Publications (1)

Publication Number Publication Date
NZ591146A true NZ591146A (en) 2012-10-26

Family

ID=41669330

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ591146A NZ591146A (en) 2008-08-14 2009-08-14 Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
NZ602248A NZ602248A (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ602248A NZ602248A (en) 2008-08-14 2009-08-14 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions

Country Status (14)

Country Link
US (6) US8637004B2 (enExample)
EP (3) EP3124601A1 (enExample)
JP (7) JP6025329B2 (enExample)
AR (2) AR073069A1 (enExample)
AU (1) AU2009281809B2 (enExample)
BR (1) BRPI0917993B8 (enExample)
CA (1) CA2733985C (enExample)
DK (1) DK2318519T3 (enExample)
ES (1) ES2608974T3 (enExample)
IL (1) IL211214A0 (enExample)
MX (2) MX362512B (enExample)
NZ (2) NZ591146A (enExample)
WO (1) WO2010019886A1 (enExample)
ZA (1) ZA201101858B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3461884B1 (en) 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
US20070258963A1 (en) 2006-01-13 2007-11-08 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing TNF-alpha receptors
EP3124601A1 (en) 2008-08-14 2017-02-01 Mesoblast International Sàrl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
ITGE20120034A1 (it) * 2012-03-28 2013-09-29 Carlo Tremolada Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
JP2013252126A (ja) * 2012-05-08 2013-12-19 Otsuka Pharmaceut Factory Inc デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
CA2899713C (en) 2013-03-15 2022-07-19 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10449283B2 (en) 2016-04-29 2019-10-22 Fenwal, Inc. System and method for selecting and culturing cells
US10251990B2 (en) 2016-04-29 2019-04-09 Fenwal, Inc. System and method for processing, incubating, and/or selecting biological cells
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10274495B2 (en) 2016-12-21 2019-04-30 Fenwal, Inc. System and method for separating cells incorporating magnetic separation
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
US20210395693A1 (en) * 2018-10-26 2021-12-23 Guy MARTI Method and apparatus for mesenchymal stem cells isolation and purification
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
TW202110463A (zh) * 2019-05-15 2021-03-16 美商永生生技股份有限公司 高濃度細胞包裝和運送
WO2021144995A1 (ja) * 2020-01-16 2021-07-22 ＰｕＲＥＣ株式会社 高純度間葉系幹細胞
AU2021267900A1 (en) 2020-05-08 2023-01-19 Gallant Pet Inc. Uterine-derived regenerative cell compositions and uses thereof
EP4314244B1 (en) 2021-03-23 2025-07-23 Terumo BCT, Inc. Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN115478046A (zh) * 2022-09-30 2022-12-16 浙江泉生生物科技有限公司 一种降低血清培养体系中细胞制剂bsa残留量的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034135A (en) * 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
WO1988001193A1 (en) 1986-08-11 1988-02-25 Hemascience Laboratories, Inc. Blood cell washing systems and methods
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5234608A (en) 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
CA2192103C (en) * 1994-06-06 2002-02-05 Arnold I. Caplan Biomatrix for tissue regeneration
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
ATE439849T1 (de) * 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US6387369B1 (en) * 1997-07-14 2002-05-14 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) * 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US6328960B1 (en) 1998-03-18 2001-12-11 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1078042A1 (en) * 1998-05-22 2001-02-28 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
FR2787463B1 (fr) 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20050048035A1 (en) * 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
KR100930139B1 (ko) * 2001-12-07 2009-12-07 사이토리 테라퓨틱스, 인크. 처리된 리포애스퍼레이트 세포로 환자를 치료하기 위한시스템 및 방법
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
ITTO20020311A1 (it) * 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
ZA200404101B (en) 2003-05-26 2005-03-07 Reliance Life Sciences Pvt Ltd In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
WO2005012480A2 (en) 2003-06-25 2005-02-10 Macropore Biosurgery Inc. Systems and methods for separating and concentrating regenerative cells from tissue
EP3461884B1 (en) * 2004-03-22 2025-05-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP3828905B2 (ja) * 2004-08-05 2006-10-04 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ 局所麻酔薬を含有する細胞凝集抑制剤
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
WO2008020815A1 (en) 2006-08-15 2008-02-21 Agency For Science, Technology And Research Mesenchymal stem cell conditioned medium
CA2663749A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7888119B2 (en) * 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
US8592209B2 (en) 2006-01-30 2013-11-26 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
CN101448527B (zh) 2006-05-19 2013-12-18 香港大学 细胞-基质微球，制备方法和应用
CA2913024A1 (en) 2006-11-03 2008-05-08 Aastrom Biosciences, Inc. Mixed cell populations for tissue repair and separation technique for cell processing
JP2008139106A (ja) * 2006-11-30 2008-06-19 Sysmex Corp 骨髄穿刺液収容具及び骨髄穿刺液濾過方法
EP2099290A4 (en) 2006-12-07 2010-01-13 Teva Pharma PROCESS FOR GENERATING AND EXPANDING PROGENITOR CELLS OF TISSUES AND TISSUE CELLS MILLED FROM INTACT BONE MARROW OR UMBILICAL INTACT CORD TISSUE
CN101210232B (zh) * 2006-12-28 2012-07-18 天津昂赛细胞基因工程有限公司 一种间充质干细胞保存液
EP2191835A4 (en) 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
US8465733B2 (en) 2007-11-02 2013-06-18 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition containing human mesenchymal stem cell
EP3124601A1 (en) 2008-08-14 2017-02-01 Mesoblast International Sàrl Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
US8048976B2 (en) 2008-09-04 2011-11-01 Amyris, Inc. Polyfarnesenes
US10476476B2 (en) 2016-12-15 2019-11-12 Murata Manufacturing Co., Ltd. MEMS resonator with suppressed spurious modes

Also Published As

Publication number Publication date
ZA201101858B (en) 2011-11-30
JP2012500214A (ja) 2012-01-05
US8637004B2 (en) 2014-01-28
EP2318519A1 (en) 2011-05-11
JP6025329B2 (ja) 2016-11-16
JP2025122125A (ja) 2025-08-20
JP2017081972A (ja) 2017-05-18
EP3124601A1 (en) 2017-02-01
JP7580202B2 (ja) 2024-11-11
NZ602248A (en) 2014-03-28
MX2011001730A (es) 2011-03-24
AU2009281809B2 (en) 2015-09-17
BRPI0917993B8 (pt) 2021-05-25
EP2318519B1 (en) 2016-10-05
JP2015071610A (ja) 2015-04-16
JP2018109052A (ja) 2018-07-12
AR073069A1 (es) 2010-10-13
EP4477742A3 (en) 2025-02-26
DK2318519T3 (en) 2017-01-16
JP2023052211A (ja) 2023-04-11
JP2020120671A (ja) 2020-08-13
IL211214A0 (en) 2011-04-28
CA2733985A1 (en) 2010-02-18
AU2009281809A1 (en) 2010-02-18
US20230089901A1 (en) 2023-03-23
AR123811A2 (es) 2023-01-18
BRPI0917993B1 (pt) 2020-12-29
US20140105872A1 (en) 2014-04-17
US20100068191A1 (en) 2010-03-18
EP4477742A2 (en) 2024-12-18
WO2010019886A1 (en) 2010-02-18
CA2733985C (en) 2016-07-12
US20250312379A1 (en) 2025-10-09
BRPI0917993A2 (pt) 2017-10-10
US20180008642A1 (en) 2018-01-11
ES2608974T3 (es) 2017-04-17
MX362512B (es) 2019-01-22
EP2318519A4 (en) 2013-07-24
US20200197444A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
NZ591146A (en) Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
UA104031C2 (uk) Диференціація мезенхімальних стовбурових клітин
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP4483952A3 (en) Compositions suitable for treating collagen-mediated diseases
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
IN2012DN01233A (enExample)
WO2010108126A3 (en) Reprogramming compositions and methods of using the same
TN2012000126A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
UA109459C2 (xx) ПОХІДНІ 5,6-ДИГІДРОІМІДАЗО[1,2-a]ПІРАЗИН-8-ІЛАМІНУ, ПРИДАТНІ ЯК ІНГІБІТОРИ БЕТА-СЕКРЕТАЗИ (BACE)
MX360598B (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
MX2011012523A (es) Esteres cetalicos de anhidropentitoles y usos de los mismos.
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
NZ627372A (en) Clostridium histolyticum enzymes and methods for the use thereof
JO2831B1 (en) Quinclidine carbonate derivatives and pharmaceutical compounds
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
PH12016500746A1 (en) A novel formulation of meloxicam
GB201213267D0 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2012000954A (es) Composicion far,aceutica topica que incuye la rel-n-[6-[(2r,6s)-2,6-dimetil-4-morfolinil]-3-piridinil]-2-metil- 4'-(trifluoro-metoxi)-[1,1'-bifenil]-3-carboxamida.
MX2010003914A (es) Nuevas composiciones a base de taxoides.
PH12012502253A1 (en) Oral care compositions and methods

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 AUG 2016 BY DENNEMEYER + CO

Effective date: 20130725

ERR Error or correction

Free format text: THE AGENT HAS BEEN CORRECTED TO 892120, FB RICE, C/- DLA PHILLIPS FOX, PO BOX 160, SHORTLAND STREET, AUCKLAND 1140, NZ; THE CONTACT HAS BEEN CORRECTED TO 892120, FB RICE, C/- DLA PHILLIPS FOX, PO BOX 160, SHORTLAND STREET, AUCKLAND 1140, NZ

Effective date: 20140715

ASS Change of ownership

Owner name: MESOBLAST INTERNATIONAL SARL C/O ACCOUNTING AN, CH

Effective date: 20150416

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2017 BY CPA GLOBAL

Effective date: 20160729

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2018 BY CPA GLOBAL

Effective date: 20170629

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2019 BY CPA GLOBAL

Effective date: 20180628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2020 BY CPA GLOBAL

Effective date: 20190628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2021 BY CPA GLOBAL

Effective date: 20200702

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2022 BY CPA GLOBAL

Effective date: 20210701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2023 BY CPA GLOBAL

Effective date: 20220630

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2024 BY CPA GLOBAL

Effective date: 20230701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240627

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 AUG 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250703